Fosun Pharmaceutical (600196.SH) subsidiary's drug approved by the U.S. FDA.

Intelligent Finance and Economics APP News, Fosun Pharma (600196.SH) announced that recently, the company's controlling subsidiary Shanghai Fosun Hanlin Biotechnology Co., Ltd. and its controlling subsidiary has received approval from the US FDA (Food and Drug Administration) for the biologics license application (BLA) of POHERDY1 (specification 420mg/14mL (30mg/mL)) injection (for intravenous use) independently developed by the company. (Pebotuzumab, project code: HLX11).